Next Phase Newsletter

A venture capital firm with offices in Europe actively invests in healthtech companies that address the global market. The firm typically invests in Seed and Series A rounds and can invest up to €5M, with additional capital reserved for follow-ons. The firm focuses on Europe-based companies. 
 
The firm is currently seeking healthtech companies that are B2B focused. The firm has invested in therapeutics, medical device, and diagnostics companies in the past. The firm prefers to invest in companies who have a commercialized product with initial revenue and traction. The firm has been opportunistic towards indication.  
 
The firm seeks to work with companies backed by an ambitious management team working on technologies with a highly scalable business model, and backed by strong IP. The firm seeks board representation in efforts to be an active partner of their portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with offices in the US looks to invest in diagnostics companies addressing gaps and answering problems present in the current market. The firm really looks to fund companies with a large market need. The firm invests exclusively in Seed to Series A rounds, with the ability for follow-on investments. The firm typically invests $1M-5M in the form of equity, with the ability to go up to $10M. The firm invests globally. 
 
The firm is solely focused on diagnostics companies. The firm is indication- and modality- agnostic, and open to all classes of diagnostics. The firm can also invest in associated data tools; however, their focus lies in diagnostics companies. The firm invests in pre-commercial companies. 
 
The firm typically co-invests. The firm likes to see management teams with diagnostic industry experience. The firm considers themselves “hands-on” investors, able to provide specific industry experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A group of angel investors operates with a fund model with an average check size of USD $100K – $500K. The firm will both lead deals and will follow-on as well as syndicate with other angel groups. The majority of deals fall within the Seed-Series A range. The group only invests in U.S.-based C-Corps.  
 
The firm is typically sector-agnostic in terms of technology and life science. Some members are more interested in early-stage Seed deals while others are looking for technologies that have been adequately de-risked. 
 
The firm is looking for privately-held, technology-based companies with experienced management teams that can demonstrate strong execution skills, potential for market dominance, high growth, and a sustainable competitive advantage. 

For deals where the firm would be acting as a co-investor, it is required that the round have a strong lead investor – i.e. one that actively negotiated the term sheet, represents a sizeable portion of the round, is taking an active role in the company (usually has a board seat) and has completed an internal due diligence effort and is willing to share the results of their due diligence effort with the firm members.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporation with over 100 years of history and multibillion dollar assets under management has a venture arm that invests in healthcare. The venture arm will be contributing to investments in biotech companies in Series A and later stage companies. The goal of this venture arm is to bring new biotech innovation to Saudi Arabia and the Middle Eastern regions. Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms. 
 
Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines. 
 
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture fund of a pharmaceutical company has their main office in the US. With its inaugural fund, the firm seeks to invest in technologies that are complementary to the parent pharma company’s R&D activities. The firm seeks to invest $5-7M as initial investment, and can invest up to $20M over the company’s lifecycle. The firm will focus on investing in companies based in the US, Western Europe, and Japan. 
 
The firm focuses on investing in therapeutics, platform technologies, and digital technologies. In therapeutics, the firm has a strong interest in cell/gene therapy, protein degraders, and covalent binders, as well as platform technologies including any platforms that can find or develop drugs across multiple therapeutic areas. Within digital technologies, the firm primarily seeks applications that help with target identification and drug design, accelerating drug discovery and development. The firm is not seeking clinical and patient-centric investments, and does not invest in medical devices or diagnostics. In terms of stage of development, the firm focuses on pre-clinical and early clinical stage opportunities. 
 
The firm does not have specific company or management team requirements. The firm does not lead investments and does not require board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A newly founded venture capital firm headquartered in the US is interested in Seed stage companies that focus on gene tech (DNA, RNA, proteins, and cells). Typical check size is expected to be around USD $500k and the firm will typically not lead rounds. Companies can have their headquarters elsewhere; however, the firm requires companies to be U.S. Incorporated. 
 
In terms of healthcare, the firm is interested in diagnostics using DNA, RNA, or proteins, cell and gene therapy, engineered vaccines, antibiotics, longevity and health span improvements, software and data, bioinformatic solutions, platforms, and AI-powered solutions. The firm is not interested in small molecules and medical devices. 

The firm does not have strict company or management team requirements. The firm does not require to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital headquartered in Europe was built on foundation of an incubator which has been operating since 2017. The firm invests in early-stage companies in the pre-seed and seed rounds, offering up to €250K tickets, with the possibility of follow-on investments. The firm invests globally, with a focus on European businesses. The firm offers convertibles and priced rounds, where the firm typically follows (or co-leads), and can assign a technical and business mentor to each team, tailoring the cooperation to the needs of each startup. 
 
The firm is sector-agnostic but exclusively focused on disruptive AI-driven solutions. The firm requires a testable prototype or proof-of-concept (POC) and initial business traction and is happy to look into B2B or B2C. 
 
The firm requires companies to have an established team of founders.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.